This study confirms the potential of Anetumab ravtansine as an anti-tumor agent, however, the results suggest that aiming on a convincing clinical outcome a further dose increase and a restriction to patients displaying a strong intratumoral Mesothelin expression might be necessary. Here, MSLN is linked to neoplasm.